3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
2
Genitourinary
2
CNS
2
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Endocrine
1
Classical hematology
1
Breast
1
Conditions
Thyroid Cancer, Papillary
2
Sarcoma
2
Salivary Gland Neoplasms
2
Brain Neoplasms
2
Wilms Tumor
1
Sarcoma, Ewing
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Neoplasm Metastasis
1
Melanoma
1
Medulloblastoma
1
Lymphoma, Large-Cell, Anaplastic
1
Head and Neck Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Advanced Thyroid Cancer Patients Who Received Target Therapy
1
Interventions
Doxorubicin
4
Sunitinib
3
Radiosurgery
3
Everolimus
3
pembrolizumab
2
exemestane
2
Tamoxifen
2
Specimen Handling
2
Octreotide
2
Magnetic Resonance Spectroscopy
2
Fulvestrant
2
Filgrastim
2
Biopsy
2
Bevacizumab
2
3-Iodobenzylguanidine
2
tislelizumab
1
surufatinib
1
romidepsin
1
regorafenib
1
penpulimab
1
pasireotide
1
mercaptoundecahydrododecaborate
1
lutetium Lu 177 dotatate
1
lanreotide
1
ganitumab
1
folfirinox
1
fludarabine phosphate
1
epothilone B
1
entrectinib
1
dostarlimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
entrectinib
×
Endocrine
×
Clear all
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA